All In Biotech

Drug Trial Radar · NCT07678827

A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Bridging Clinical Trial to Evaluate the Efficacy and Safety of Viloxazine Extended-Release (ER) Capsules (AK-D101) in Korean Children and Adolescents (6-17 Years of Age) With Attention-Deficit/Hyperactivity Disorder (ADHD)

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Alvogen KoreaIndustry
Sponsor type
Industry
First posted
Jul 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter bridging clinical trial designed to evaluate the efficacy and safety of viloxazine extended-release capsules (AK-D101) compared with placebo in Korean children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder (ADHD). Eligible participants will be randomized in a 1:1 ratio to receive AK-D101 or placebo once daily for 8 weeks. Randomization will be stratified by study site and age group (children aged 6 to 11 years and adolescents aged 12 to 17 years). The primary efficacy endpoint is the change from baseline to Week 8, End of Treatment, in the Korean ADHD Rating Scale, 5th Edition (K-ARS-5) Total Score.

Conditions

  • Attention Deficit Hyperactivity Disorder
  • Attention-Deficit / Hyperactivity Disorder
  • ADHD

Interventions

  • AK-D101Drug

    Viloxazine extended-release capsules administered orally once daily in the morning for 8 weeks. The starting dose is 100 mg once daily. The dose may be increased by 100 mg weekly during titration, up to 400 mg once daily, based on investigator assessment of tolerability and response. The maintenance dose will be 200 mg, 300 mg, or 400 mg once daily.

  • PlaceboDrug

    Matching placebo capsules administered orally once daily in the morning for 8 weeks. Mock titration will be performed to maintain blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 8 in K-ARS-5 (Korean ADHD Rating Scale, 5th Edition) Total ScoreTime frame: Baseline to Week 8, End of Treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.